DAPK2

Summary

DAPK2 (death associated protein kinase 2, HGNC:2675) is a protein-coding gene on chromosome 15q22.31, encoding Death-associated protein kinase 2 (Q9UIK4). Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy.

This gene encodes a protein that belongs to the serine/threonine protein kinase family. This protein contains a N-terminal protein kinase domain followed by a conserved calmodulin-binding domain with significant similarity to that of death-associated protein kinase 1 (DAPK1), a positive regulator of programmed cell death. Overexpression of this gene was shown to induce cell apoptosis. It uses multiple polyadenylation sites.

Source: NCBI Gene 23604 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 86 total
• Druggable target: yes — 13 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_014326

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2675
Approved symbol	DAPK2
Name	death associated protein kinase 2
Location	15q22.31
Locus type	gene with protein product
Status	Approved
Aliases	DRP-1, MGC119312
Ensembl gene	ENSG00000035664
Ensembl biotype	protein_coding
OMIM	616567
Entrez	23604

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 9 protein_coding, 3 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000261891, ENST00000457488, ENST00000557867, ENST00000558064, ENST00000558069, ENST00000558076, ENST00000558482, ENST00000559007, ENST00000559306, ENST00000559731, ENST00000559897, ENST00000561162, ENST00000612884, ENST00000908660, ENST00000908661, ENST00000943723, ENST00000943724

RefSeq mRNA: 20 — MANE Select: NM_014326 NM_001363730, NM_001384997, NM_001384998, NM_001384999, NM_001385000, NM_001395279, NM_001395281, NM_001395282, NM_001395283, NM_001395284, NM_001395285, NM_001395286, NM_001395287, NM_001395288, NM_001395289, NM_001395290, NM_001395291, NM_001395292, NM_001395293, NM_014326

CCDS: CCDS10188, CCDS86463

Canonical transcript exons

ENST00000457488 — 12 exons

Exon	Start	End
ENSE00001281614	63907036	63908600
ENSE00003466541	63971423	63971561
ENSE00003473652	64040170	64040267
ENSE00003487172	63912108	63912197
ENSE00003529418	63929551	63929577
ENSE00003535596	63939232	63939361
ENSE00003587735	63930407	63930455
ENSE00003591892	63983533	63983754
ENSE00003652942	63924816	63924861
ENSE00003680892	63925941	63926093
ENSE00003688429	63911908	63911991
ENSE00003978112	64046298	64046485

Expression profiles

Bgee: expression breadth ubiquitous, 250 present calls, max score 96.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.5947 / max 371.8702, expressed in 1025 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150447	3.5947	1025

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of thyroid gland	UBERON:0001119	96.74	gold quality
left lobe of thyroid gland	UBERON:0001120	95.73	gold quality
right atrium auricular region	UBERON:0006631	95.28	gold quality
thyroid gland	UBERON:0002046	95.14	gold quality
right lung	UBERON:0002167	94.92	gold quality
cardiac atrium	UBERON:0002081	94.72	gold quality
gastrocnemius	UBERON:0001388	94.65	gold quality
muscle of leg	UBERON:0001383	94.01	gold quality
hindlimb stylopod muscle	UBERON:0004252	93.52	gold quality
muscle organ	UBERON:0001630	91.51	gold quality
type B pancreatic cell	CL:0000169	91.39	gold quality
olfactory bulb	UBERON:0002264	91.25	gold quality
upper lobe of left lung	UBERON:0008952	91.25	gold quality
heart left ventricle	UBERON:0002084	90.56	gold quality
upper lobe of lung	UBERON:0008948	90.47	gold quality
cardiac ventricle	UBERON:0002082	90.33	gold quality
blood	UBERON:0000178	90.26	gold quality
heart	UBERON:0000948	88.84	gold quality
sural nerve	UBERON:0015488	88.81	gold quality
apex of heart	UBERON:0002098	88.80	gold quality
cardiac muscle of right atrium	UBERON:0003379	87.57	gold quality
left ventricle myocardium	UBERON:0006566	87.53	silver quality
duodenum	UBERON:0002114	87.36	gold quality
hair follicle	UBERON:0002073	87.11	gold quality
lung	UBERON:0002048	86.88	gold quality
myocardium	UBERON:0002349	86.68	gold quality
diaphragm	UBERON:0001103	86.48	gold quality
mucosa of transverse colon	UBERON:0004991	86.27	gold quality
buccal mucosa cell	CL:0002336	86.10	silver quality
skeletal muscle tissue	UBERON:0001134	86.06	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	14.46

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, CTNNB1, E2F1, KLF6, RARA, SP1, SPI1, TCF7L2

miRNA regulators (miRDB)

59 targeting DAPK2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4531	99.99	69.70	3181
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-4687-5P	99.14	66.26	488

Literature-anchored findings (GeneRIF, showing 27)

• High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients (PMID:11839660)
• distinct methylation pattern in bladder cancer with frequent methylation of RARbeta, DAPK, E-cadherin, and p16. (PMID:11839665)
• gene expression in colorectal and gastric cancer silenced by DNA methylation and histone deacetylation (PMID:12087472)
• Results implicate a novel role for DAPK2 in the regulation of normal myelopoiesis. (PMID:17347302)
• DAPK2 as a novel Sp1-dependent target gene for E2F1 and KLF6 in cell death response. (PMID:18521079)
• beta-catenin-induced down-regulation of DAPk-2 represents a novel signaling mechanism by which beta-catenin promotes the survival of malignant epithelial cells (PMID:18957423)
• Results showed that the inactivation of RASSF1A, RARbeta2 and DAP-Kinase by hypermethylation is a key step in NPC tumorigenesis and progression. (PMID:19221469)
• DRP-1 and ZIPk most likely evolved from their ancient ancestor gene DAPk by two gene duplication events that occurred close to the emergence of vertebrates (PMID:21408167)
• Sodium butyrate induced DAPK1/2 expression in human gastric cancer cells and this expression prompted apoptosis by decreasing FAK levels. (PMID:22160140)
• DAPK2 is upregulated in uterosacral ligaments in pelvic organ prolapse (PMID:23700042)
• The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPalpha during granulocytic differentiation but repressed by PML-RARalpha in APL. (PMID:24038216)
• The defect in chemotaxis in DAPK2-inactive granulocytes is likely a result of reduced polarization of the cells, mediated by a lack of MLC phosphorylation, resulting in radial F-actin and pseudopod formation. (PMID:24163421)
• DAPK2 is a novel kinase of mTORC1 and is a potential new member of this multiprotein complex, modulating mTORC1 activity and autophagy levels under stress and steady-state conditions. (PMID:25361081)
• DAPK2 regulates oxidative stress in cancer cells by preserving mitochondrial function (PMID:25741596)
• miR-520h suppresses Death-associated protein kinase 2 (DAPK2) expression, as restoring DAPK2 abolished miR-520h-promoted drug resistance, and knockdown of DAPK2 mitigated cell death caused by the depletion of miR-520h. (PMID:25982274)
• This study links adipocyte expression of an autophagy-regulating kinase, lysosome-mediated clearance and fat cell lipid accumulation; it demonstrates obesity-related attenuated autophagy in adipocytes, and identifies DAPK2 dependence in this regulation. (PMID:26038578)
• DAPK2-induced apoptosis is negatively regulated by Akt and 14-3-3 proteins. (PMID:26047703)
• that Death-associated protein kinase 2 effector functions are influenced by the protein’s subcellular localization (PMID:26483415)
• This study suggests that miR-520g contributes to tumor progression and drug resistance by post-transcriptionally downregulating DAPK2 in patients with epithelial ovarian cancer (PMID:27049921)
• Thyroid hormone promotes selective autophagy via induction of DAPK2-SQSTM1 cascade, which in turn protects hepatocytes from diethylnitrosamine-induced hepatotoxicity or carcinogenesis. (PMID:27653365)
• study reveals a unique calmodulin-independent mechanism for DAPK2 activation, critical to its function as a novel downstream effector of AMPK in autophagy (PMID:29717115)
• remission effect of DAPK2 on placental cell oxidative damage and apoptosis in HDCP via mTOR activation (PMID:30243997)
• The intracellular signaling pathways that lead to Ser289 phosphorylation are mutually-exclusive and different for each kinase. In addition, Ser289 phosphorylation in fact enhances DAPK1 catalytic activity, similar to the effect on DAPK2. Thus, Ser289 phosphorylation activates both DAPK1 and DAPK2, but in response to different intracellular signaling pathways. (PMID:31116076)
• miR-1285-3p Controls Colorectal Cancer Proliferation and Escape from Apoptosis through DAPK2. (PMID:32244500)
• Cigarette smoking induces aberrant N(6)-methyladenosine of DAPK2 to promote non-small cell lung cancer progression by activating NF-kappaB pathway. (PMID:34298122)
• 14-3-3 proteins inactivate DAPK2 by promoting its dimerization and protecting key regulatory phosphosites. (PMID:34413451)
• Exosomal miR-133a-3p Derived from BMSCs Alleviates Cerebral Ischemia-Reperfusion Injury via Targeting DAPK2. (PMID:36636640)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dapk2a	ENSDARG00000061096
danio_rerio	dapk2b	ENSDARG00000103666
mus_musculus	Dapk2	ENSMUSG00000032380
rattus_norvegicus	Dapk2	ENSRNOG00000017332

Paralogs (4): MYLK (ENSG00000065534), NEXN (ENSG00000162614), DAPK3 (ENSG00000167657), DAPK1 (ENSG00000196730)

Protein

Protein identifiers

Death-associated protein kinase 2 — Q9UIK4 (reviewed: Q9UIK4)

Alternative names: DAP-kinase-related protein 1

All UniProt accessions (5): Q9UIK4, H0YKW8, H0YL86, H0YLP5, H0YMK1

UniProt curated annotations — full annotation on UniProt →

Function. Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy. Regulates both type I apoptotic and type II autophagic cell death signals, depending on the cellular setting. The former is caspase-dependent, while the latter is caspase-independent and is characterized by the accumulation of autophagic vesicles. Acts as a mediator of anoikis and a suppressor of beta-catenin-dependent anchorage-independent growth of malignant epithelial cells. May play a role in granulocytic maturation. Regulates granulocytic motility by controlling cell spreading and polarization. Isoform 2 is not regulated by calmodulin. It can phosphorylate MYL9. It can induce membrane blebbing and autophagic cell death.

Subunit / interactions. Homodimer in its autoinhibited state. Active as monomer. Isoform 2 but not isoform 1 can interact with ATF4. Interacts with 14-3-3 proteins YWHAB, YWHAE, YWHAG, YWHAH, YWHAQ, YWHAZ and SFN; the interaction requires DAPK2 phosphorylation at Thr-369 and suppresses DAPK2 kinase activity and DAPK2-induced apoptosis.

Subcellular location. Cytoplasm. Cytoplasmic vesicle. Autophagosome lumen.

Tissue specificity. Expressed in neutrophils and eosinophils. Isoform 2 is expressed in embryonic stem cells (at protein level). Isoform 1 is ubiquitously expressed in all tissue types examined with high levels in heart, lung and skeletal muscle.

Post-translational modifications. Autophosphorylation at Ser-318 inhibits its catalytic activity. Dephosphorylated at Ser-318 in response to activated Fas and TNF receptors.

Activity regulation. Activated by Ca(2+)/calmodulin. Regulated by a double locking mechanism, involving autophosphorylation at Ser-318, calmodulin binding, and dimerization. In the inactive state, Ser-318 is phosphorylated, and the kinase is dimeric. Activation involves: dephosphorylation at Ser-318, release-of-autoinhibition mechanism where calmodulin binding induces a conformational change that relieves the steric block of the active site by the autoinhibitory domain, and generation of the monomeric active form of the kinase.

Domain organisation. The autoinhibitory domain sterically blocks the substrate peptide-binding site by making both hydrophobic and electrostatic contacts with the kinase core.

Induction. Up-regulated during granulocytic maturation.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. DAP kinase subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UIK4-1	1, Alpha	yes
Q9UIK4-2	2, Beta

RefSeq proteins (20): NP_001350659, NP_001371926, NP_001371927, NP_001371928, NP_001371929, NP_001382208, NP_001382210, NP_001382211, NP_001382212, NP_001382213, NP_001382214, NP_001382215, NP_001382216, NP_001382217, NP_001382218, NP_001382219, NP_001382220, NP_001382221, NP_001382222, NP_055141* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (60 total): helix 15, mutagenesis site 12, strand 11, modified residue 4, region of interest 4, turn 3, sequence variant 2, sequence conflict 2, binding site 2, chain 1, domain 1, splice variant 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
2A2A	X-RAY DIFFRACTION	1.47
1ZUZ	X-RAY DIFFRACTION	1.91
1WRZ	X-RAY DIFFRACTION	2
7A6Y	X-RAY DIFFRACTION	2.5
7A6R	X-RAY DIFFRACTION	2.7
2CKE	X-RAY DIFFRACTION	2.8
1ZWS	X-RAY DIFFRACTION	2.9
6PAW	X-RAY DIFFRACTION	2.95
2A27	X-RAY DIFFRACTION	3
1WMK	X-RAY DIFFRACTION	3.6
1Z9X	X-RAY DIFFRACTION	3.93

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UIK4-F1	86.41	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 149 (proton acceptor)

Ligand- & substrate-binding residues (2): 29–37; 52

Post-translational modifications (4): 318, 349, 369, 299

Mutagenesis-validated functional residues (12):

Position	Phenotype
52	loss of activity, apoptotic function and of autophosphorylation.
299–330	loss of ca(2+)-calmodulin binding, increase in activity, loss of autophosphorylation.
299	no effect on ca(2+)-calmodulin independent phosphorylation or apoptotic activity.
318	loss of ca(2+)-calmodulin independent phosphorylation, increase in apoptotic activity.
318	abolishes apoptotic activity.
320	no effect on ca(2+)-calmodulin independent phosphorylation or apoptotic activity.
323	no effect on ca(2+)-calmodulin independent phosphorylation or apoptotic activity.
329	no effect on ca(2+)-calmodulin independent phosphorylation or apoptotic activity.
367	no effect on interaction with ywhae.
368	no effect on interaction with ywhae.
369	interaction with ywhae is reduced.
370	interaction with ywhae is increased.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-418889	Caspase activation via Dependence Receptors in the absence of ligand

MSigDB gene sets: 244 (showing top): MORF_RAGE, GOBP_REGULATION_OF_AUTOPHAGY, MORF_FLT1, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_CELL_CHEMOTAXIS, MODULE_45, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, MORF_ESR1, MODULE_16, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_LEUKOCYTE_CHEMOTAXIS, MODULE_118

GO Biological Process (12): protein phosphorylation (GO:0006468), apoptotic process (GO:0006915), regulation of autophagy (GO:0010506), intracellular signal transduction (GO:0035556), regulation of apoptotic process (GO:0042981), positive regulation of apoptotic process (GO:0043065), anoikis (GO:0043276), protein autophosphorylation (GO:0046777), positive regulation of neutrophil chemotaxis (GO:0090023), neutrophil migration (GO:1990266), positive regulation of eosinophil chemotaxis (GO:2000424), regulation of intrinsic apoptotic signaling pathway (GO:2001242)

GO Molecular Function (10): protein serine/threonine kinase activity (GO:0004674), calmodulin binding (GO:0005516), ATP binding (GO:0005524), identical protein binding (GO:0042802), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), cytoplasmic vesicle (GO:0031410), autophagosome lumen (GO:0034423), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Caspase activation via extrinsic apoptotic signalling pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
apoptotic process	3
intracellular anatomical structure	2
positive regulation of granulocyte chemotaxis	2
protein kinase activity	2
protein binding	2
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
cytoplasm	2
phosphorylation	1
protein modification process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
autophagy	1
regulation of catabolic process	1
signal transduction	1
regulation of programmed cell death	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
protein phosphorylation	1
neutrophil chemotaxis	1
regulation of neutrophil chemotaxis	1
positive regulation of neutrophil migration	1
granulocyte migration	1
eosinophil chemotaxis	1
positive regulation of eosinophil migration	1
regulation of eosinophil chemotaxis	1
intrinsic apoptotic signaling pathway	1
regulation of intracellular signal transduction	1
regulation of apoptotic signaling pathway	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1

Protein interactions and networks

STRING

1761 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DAPK2	CALML3	P27482	825
DAPK2	CALML5	Q9NZT1	825
DAPK2	CALML6	Q8TD86	813
DAPK2	CALML4	Q96GE6	813
DAPK2	CALM1	P02593	740
DAPK2	BECN1	Q14457	736
DAPK2	ATG14	Q6ZNE5	620
DAPK2	UNC5B	Q8IZJ1	573
DAPK2	VMP1	Q96GC9	529
DAPK2	MGMT	P16455	510
DAPK2	IFNG	P01579	507
DAPK2	RASSF1	Q9NS23	507
DAPK2	PIK3C3	Q8NEB9	503
DAPK2	TMEM74	Q96NL1	496
DAPK2	MIB1	Q86YT6	486
DAPK2	MAP1LC3C	Q9BXW4	486

IntAct

21 interactions, top by confidence:

A	B	Type	Score
DAPK2	FAM9B	psi-mi:“MI:0915”(physical association)	0.670
DAPK2	DAPK2	psi-mi:“MI:0915”(physical association)	0.590
CCDC91	DAPK2	psi-mi:“MI:0915”(physical association)	0.560
DAPK2	YWHAE	psi-mi:“MI:0915”(physical association)	0.400
SFN	DAPK2	psi-mi:“MI:0915”(physical association)	0.400
Bub1	PEX10	psi-mi:“MI:0914”(association)	0.350
RACGAP1	STX18	psi-mi:“MI:0914”(association)	0.350
LLGL2	RBBP6	psi-mi:“MI:0914”(association)	0.350
TUBGCP5	DNAJC6	psi-mi:“MI:0914”(association)	0.350
KLC3	KLC1	psi-mi:“MI:0914”(association)	0.350
SLK	ENSA	psi-mi:“MI:0914”(association)	0.350
DAPK2	CCDC91	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (20): DAPK2 (Biochemical Activity), FAM9B (Two-hybrid), DAPK2 (Affinity Capture-MS), DAPK2 (Affinity Capture-MS), DAPK2 (Affinity Capture-MS), DAPK2 (Affinity Capture-MS), DAPK2 (Affinity Capture-MS), TP73 (Affinity Capture-Western), ATG5 (Affinity Capture-Western), CCDC91 (Two-hybrid), DAPK2 (Proximity Label-MS), DAPK2 (Affinity Capture-MS), DAPK2 (Affinity Capture-MS), DAPK2 (Affinity Capture-Western), DAPK2 (Affinity Capture-MS)

ESM2 similar proteins: A8X6H4, O70150, O75582, P10665, P11275, P11798, P18652, P18653, P18654, P28583, P51812, Q13557, Q14012, Q15349, Q2HJF7, Q38869, Q38871, Q38872, Q39016, Q42396, Q54CY9, Q54SJ5, Q5F3L1, Q5R4K3, Q5RCC4, Q5ZKI0, Q63450, Q63531, Q6DEH3, Q6GLS4, Q6P2M8, Q6PFQ0, Q6PHZ2, Q7TPS0, Q869W6, Q8BW96, Q8IU85, Q8RWL2, Q8VDF3, Q91YS8

Diamond homologs: A0A509AFG4, A0A5K1K8H0, A2AAJ9, A2ZVI7, A4IFM7, A8C984, A8WXF6, B9FKW9, C0HKC8, C0HKC9, E9PT87, O02827, O43293, O44997, O54784, O62305, O70150, O75147, O80673, O88764, O94768, P07313, P08414, P11801, P13234, P15735, P18653, P20689, P29294, P31325, P34101, P43292, P53355, P53681, Q00168, Q00771, Q0KHT7, Q0V7M1, Q10KY3, Q14012

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
DAPK2	“down-regulates activity”	DAPK2	phosphorylation
DAPK2	“down-regulates activity”	RPTOR	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 16 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Membrane Trafficking	6	18.5×	3e-05
Vesicle-mediated transport	6	17.4×	3e-05
Signaling by Rho GTPases	5	14.2×	5e-04
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	5	13.9×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

86 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

3007 predictions. Top by Δscore:

Variant	Effect	Δscore
15:63911900:TTAC:T	donor_loss	1.0000
15:63911903:CCCA:C	donor_gain	1.0000
15:63911905:CA:C	donor_loss	1.0000
15:63911906:A:C	donor_loss	1.0000
15:63911987:GAAAG:G	acceptor_gain	1.0000
15:63911988:AAAG:A	acceptor_gain	1.0000
15:63911989:AAG:A	acceptor_gain	1.0000
15:63911990:AG:A	acceptor_gain	1.0000
15:63911992:C:CC	acceptor_gain	1.0000
15:63912002:C:CT	acceptor_gain	1.0000
15:63912128:A:AC	donor_gain	1.0000
15:63912129:C:CC	donor_gain	1.0000
15:63912134:T:TA	donor_gain	1.0000
15:63939376:G:GC	acceptor_gain	1.0000
15:63968923:A:T	acceptor_gain	1.0000
15:63983529:TCACA:T	donor_loss	1.0000
15:63983530:CA:C	donor_loss	1.0000
15:63983531:A:AC	donor_gain	1.0000
15:63983531:AC:A	donor_loss	1.0000
15:63983531:ACAG:A	donor_gain	1.0000
15:63983532:C:CA	donor_gain	1.0000
15:63983532:CA:C	donor_gain	1.0000
15:63983532:CAG:C	donor_gain	1.0000
15:63983532:CAGC:C	donor_gain	1.0000
15:63983532:CAGCT:C	donor_gain	1.0000
15:63983750:GGCCA:G	acceptor_gain	1.0000
15:63983751:GCCA:G	acceptor_gain	1.0000
15:63983751:GCCAC:G	acceptor_gain	1.0000
15:63983752:CCA:C	acceptor_gain	1.0000
15:63983752:CCAC:C	acceptor_gain	1.0000

AlphaMissense

2472 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:63924824:A:G	W284R	1.000
15:63924824:A:T	W284R	1.000
15:63929569:C:T	G214D	1.000
15:63930408:A:G	W211R	1.000
15:63930408:A:T	W211R	1.000
15:63939236:A:C	F193L	1.000
15:63939236:A:T	F193L	1.000
15:63939238:A:G	F193L	1.000
15:63939249:C:T	G189E	1.000
15:63939291:G:T	A175D	1.000
15:63939302:G:C	D171E	1.000
15:63939302:G:T	D171E	1.000
15:63939303:T:A	D171V	1.000
15:63939303:T:C	D171G	1.000
15:63939303:T:G	D171A	1.000
15:63939304:C:G	D171H	1.000
15:63939353:G:C	N154K	1.000
15:63939353:G:T	N154K	1.000
15:63971423:C:A	K151N	1.000
15:63971423:C:G	K151N	1.000
15:63971427:A:G	L150P	1.000
15:63971430:T:A	D149V	1.000
15:63971470:C:A	G136W	1.000
15:63983691:C:A	K52N	1.000
15:63983691:C:G	K52N	1.000
15:63983745:A:C	F34L	1.000
15:63983745:A:T	F34L	1.000
15:63983747:A:G	F34L	1.000
15:63924822:C:A	W284C	0.999
15:63924822:C:G	W284C	0.999

dbSNP variants (sampled 300 via entrez): RS1000107348 (15:63935552 C>T), RS1000145543 (15:63918191 C>A,G,T), RS1000151449 (15:63926045 C>T), RS1000159768 (15:63957927 G>A), RS1000168350 (15:64032856 T>C), RS1000186708 (15:63999802 G>A), RS1000199066 (15:64022736 T>C), RS1000209320 (15:63954313 T>C), RS1000223287 (15:63937992 A>G), RS1000257474 (15:64028669 T>C), RS1000259669 (15:63971369 G>A), RS1000284577 (15:64010962 G>A), RS1000286353 (15:64045314 T>A), RS1000311443 (15:63965235 G>A,C), RS1000331546 (15:63923744 A>G)

Disease associations

OMIM: gene MIM:616567 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST004068_48	Venous thromboembolism adjusted for sickle cell variant rs77121243-T	3.000000e-06
GCST004490_24	Cerebrospinal fluid t-tau:AB1-42 ratio	3.000000e-08
GCST004616_62	Platelet distribution width	6.000000e-10
GCST006904_4	Cerebral amyloid deposition (PET imaging)	1.000000e-06
GCST008403_12	Arterial stiffness index	1.000000e-06
GCST009507_6	Triglyceride levels	1.000000e-07
GCST010242_40	HDL cholesterol levels	4.000000e-15
GCST010250_2	Systolic blood pressure x dichotomous lifestyle risk score interaction (2df test)	3.000000e-06
GCST010251_1	Systolic blood pressure x dichotomous lifestyle risk score interaction (1df test)	5.000000e-07

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007708	t-tau:beta-amyloid 1-42 ratio measurement
EFO:0007984	platelet component distribution width
EFO:0007707	cerebral amyloid deposition measurement
EFO:0004517	arterial stiffness measurement
EFO:0004530	triglyceride measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0006335	systolic blood pressure
EFO:0010724	lifestyle measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3123 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

13 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 116,167 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL603469	LESTAURTINIB	3
CHEMBL91829	RUBOXISTAURIN	3	77
CHEMBL1721885	SU-014813	2	363
CHEMBL475251	R-406	2	762
CHEMBL513909	BI-2536	2	895
CHEMBL1908394	GSK-461364	1	1,093
CHEMBL1908397	KW-2449	1	622
CHEMBL259084	MLN-8054	1	2,430

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Death-associated kinase (DAPK) family

Binding affinities (BindingDB)

5 measured of 5 human assays (5 total across all organisms); most potent 5 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
PKC-412	KD	190 nM
3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol	KD	2400 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM

ChEMBL bioactivities

53 potent at pChembl≥5 of 55 total, top 44 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.80	Kd	1.6	nM	STAUROSPORINE
8.52	Kd	3	nM	STAUROSPORINE
8.28	IC50	5.21	nM	STAUROSPORINE
8.26	IC50	5.56	nM	STAUROSPORINE
8.14	IC50	7.25	nM	STAUROSPORINE
8.00	IC50	10	nM	CHEMBL3103192
7.66	IC50	22	nM	CHEMBL4764610
7.54	Kd	29	nM	FEDRATINIB
7.47	Kd	34	nM	CHEMBL4465866
7.22	Kd	60	nM	CHEMBL4576489
7.21	Kd	62	nM	R-406
7.20	Kd	63	nM	LESTAURTINIB
7.10	Kd	79	nM	CHEMBL5303531
7.03	Kd	94	nM	CHEMBL1241674
7.01	Kd	97	nM	RUXOLITINIB
6.82	Kd	150	nM	SUNITINIB
6.77	IC50	170	nM	CHEMBL3799389
6.40	Kd	400	nM	SU-014813
6.35	Kd	450	nM	CHEMBL3921246
6.33	Kd	470	nM	SUNITINIB
6.24	IC50	570	nM	CHEMBL3797466
6.23	IC50	590	nM	CHEMBL3799585
6.21	Kd	610	nM	SP-600125
6.08	IC50	830	nM	CHEMBL513703
6.06	Kd	870	nM	TAE-684
6.05	Kd	890	nM	MIDOSTAURIN
6.03	Kd	930	nM	BI-2536
6.00	IC50	1000	nM	TP-030-1
6.00	IC50	1000	nM	TP-030-2
6.00	IC50	1000	nM	TP-030n
5.96	Kd	1100	nM	CHEMBL464552
5.89	Kd	1300	nM	CHEMBL2425628
5.75	Kd	1800	nM	KW-2449
5.64	IC50	2300	nM	CHEMBL3797480
5.60	IC50	2512	nM	CHEMBL5549980
5.60	Kd	2500	nM	CHEMBL379218
5.58	Kd	2600	nM	RUBOXISTAURIN
5.57	Kd	2700	nM	PI-103
5.54	Kd	2900	nM	GSK-461364
5.51	IC50	3070	nM	SULFURETIN
5.50	Kd	3200	nM	NINTEDANIB
5.47	Kd	3400	nM	CHEMBL1908395
5.20	IC50	6340	nM	CHEMBL4087337
5.04	Kd	9100	nM	MLN-8054

PubChem BioAssay actives

50 with measured affinity, of 663 total; 36 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	435153: Binding constant for full-length DAPK2	kd	0.0016	uM
N-[2-[2-aminoethyl(methyl)amino]-5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]phenyl]acetamide	1301624: Inhibition of Dapk2 (unknown origin) by quantitative PCR	ic50	0.0100	uM
4-fluoro-2-methoxy-11-oxo-5-propan-2-yl-3-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-6H-indolo[2,3-b]quinoline-8-carbonitrile	1700701: Inhibition of human DAPK2	ic50	0.0220	uM
Fedratinib	625077: Binding constant for DAPK2 kinase domain	kd	0.0290	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526172: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged DAPK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.0340	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylamino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526172: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged DAPK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.0600	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	625077: Binding constant for DAPK2 kinase domain	kd	0.0620	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507893: Binding affinity to DAPK2	kd	0.0630	uM
2-[[1-(3-chlorophenyl)-4-oxo-5H-pyrazolo[5,4-d]pyrimidin-6-yl]sulfanyl]propanamide	1966660: Binding affinity to DAPK2 (unknown origin) assessed as dissociation constant	kd	0.0790	uM
2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	625077: Binding constant for DAPK2 kinase domain	kd	0.0940	uM
Ruxolitinib	625077: Binding constant for DAPK2 kinase domain	kd	0.0970	uM
Sunitinib	435153: Binding constant for full-length DAPK2	kd	0.1500	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]cyclopropanecarboxamide	1298196: Inhibition of DAPK2 (unknown origin)	ic50	0.1700	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	435153: Binding constant for full-length DAPK2	kd	0.4000	uM
6-[[4-[(Z)-[2-(4-ethylphenyl)imino-3-methyl-4-oxo-1,3-thiazolidin-5-ylidene]methyl]-2-pyridinyl]amino]pyridine-3-carboxylic acid	1323334: Binding affinity to human DAPK2 expressed in Escherichia coli BL21 cells incubated for 1 hr by active site directed binding competition assay	kd	0.4500	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]-3-methylbut-2-enamide	1298196: Inhibition of DAPK2 (unknown origin)	ic50	0.5700	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]butanamide	1298196: Inhibition of DAPK2 (unknown origin)	ic50	0.5900	uM
14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one	256651: Average Binding Constant for DAPK2; NA=Not Active at 10 uM	kd	0.6100	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]-2,2-dimethylpropanamide	1298196: Inhibition of DAPK2 (unknown origin)	ic50	0.8300	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	625077: Binding constant for DAPK2 kinase domain	kd	0.8700	uM
Midostaurin	435153: Binding constant for full-length DAPK2	kd	0.8900	uM
4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	625077: Binding constant for DAPK2 kinase domain	kd	0.9300	uM
2-[[2-[[1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide	625077: Binding constant for DAPK2 kinase domain	kd	1.1000	uM
(4-hydroxypiperidin-1-yl)-[4-[[4-[4-(3-methylsulfonylpropoxy)indol-1-yl]pyrimidin-2-yl]amino]cyclohexyl]methanone	769524: Binding affinity to DAPK2 (unknown origin)	kd	1.3000	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	625077: Binding constant for DAPK2 kinase domain	kd	1.8000	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]pentanamide	1298196: Inhibition of DAPK2 (unknown origin)	ic50	2.3000	uM
(2S)-1-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-3-phenylpropan-2-amine	625077: Binding constant for DAPK2 kinase domain	kd	2.5000	uM
5-[4-[2-aminoethyl(ethyl)amino]-3-(1,2,4-triazol-4-yl)anilino]-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile	2066655: Inhibition of human DAPK2 expressed in HEK293 cells incubated for 2 hrs by NanoBRET assay	ic50	2.5119	uM
(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione	256651: Average Binding Constant for DAPK2; NA=Not Active at 10 uM	kd	2.6000	uM
3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenol	435153: Binding constant for full-length DAPK2	kd	2.7000	uM
5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide	625077: Binding constant for DAPK2 kinase domain	kd	2.9000	uM
(2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-6-hydroxy-1-benzofuran-3-one	1446697: Inhibition of human DAPK2	ic50	3.0700	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	625077: Binding constant for DAPK2 kinase domain	kd	3.2000	uM
5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide;hydrochloride	625077: Binding constant for DAPK2 kinase domain	kd	3.4000	uM
(2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-5-methoxy-1-benzofuran-3-one	1446697: Inhibition of human DAPK2	ic50	6.3400	uM
4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid	625077: Binding constant for DAPK2 kinase domain	kd	9.1000	uM

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	affects binding, affects reaction, increases reaction, increases expression	4
sodium arsenite	decreases expression, affects cotreatment, increases abundance	3
Estradiol	increases expression, increases reaction	3
Valproic Acid	affects cotreatment, decreases expression, increases methylation	3
Aflatoxin B1	decreases expression, decreases methylation	3
Particulate Matter	increases abundance, decreases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
lead acetate	decreases expression	1
trichostatin A	increases expression	1
perfluorooctanoic acid	increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	decreases methylation	1
cupric chloride	decreases expression	1
bafilomycin A	affects reaction, increases expression, increases reaction	1
tamibarotene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
usnic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
cacalol	increases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
jinfukang	affects cotreatment, decreases expression	1
Bortezomib	decreases expression, increases response to substance	1
Decitabine	increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases cleavage, increases expression, affects reaction	1
Vorinostat	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Amiodarone	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1

ChEMBL screening assays

185 unique, capped per target: 185 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1034094	Binding	Inhibition of DAPK2 at 3 uM	Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SK33	HAP1 DAPK2 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.